Press Release: TEVA : Medincell's Partner Teva Presented Phase 3 Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with Olanzapine LAI
Regulatory News: Medincell (Paris:MEDCL): More than 92% of schizophrenia patients taking Olanzapine LAI in the Phase 3 SOLARIS survey were satisfied or very
Read full article »
Teva is an Israel-based pharmaceutical company that develops and commercializes generic drugs for the treatment of cancer and respiratory diseases around the world.
Read more